Prime Medicine Statistics

Total Valuation

Prime Medicine has a market cap or net worth of $186.62 million. The enterprise value is $163.51 million.

Market Cap	186.62M
Enterprise Value	163.51M

Important Dates

The next estimated earnings date is Monday, August 4, 2025, after market close.

Earnings Date	Aug 4, 2025
Ex-Dividend Date	n/a

Share Statistics

Prime Medicine has 127.82 million shares outstanding. The number of shares has increased by 32.05% in one year.

Current Share Class	127.82M
Shares Outstanding	127.82M
Shares Change (YoY)	+32.05%
Shares Change (QoQ)	-0.03%
Owned by Insiders (%)	20.16%
Owned by Institutions (%)	38.70%
Float	60.53M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	47.53
Forward PS	166.33
PB Ratio	1.74
P/TBV Ratio	1.75
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	42.52
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 4.78, with a Debt / Equity ratio of 1.13.

Current Ratio	4.78
Quick Ratio	4.21
Debt / Equity	1.13
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -115.21% and return on invested capital (ROIC) is -50.06%.

Return on Equity (ROE)	-115.21%
Return on Assets (ROA)	-40.36%
Return on Invested Capital (ROIC)	-50.06%
Return on Capital Employed (ROCE)	-70.27%
Revenue Per Employee	$17,972
Profits Per Employee	-$943,977
Employee Count	214
Asset Turnover	0.01
Inventory Turnover	n/a

Taxes

Income Tax	-134,000
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -80.99% in the last 52 weeks. The beta is 1.55, so Prime Medicine's price volatility has been higher than the market average.

Beta (5Y)	1.55
52-Week Price Change	-80.99%
50-Day Moving Average	1.41
200-Day Moving Average	2.72
Relative Strength Index (RSI)	51.68
Average Volume (20 Days)	2,714,066

Short Selling Information

The latest short interest is 17.97 million, so 14.06% of the outstanding shares have been sold short.

Short Interest	17.97M
Short Previous Month	17.70M
Short % of Shares Out	14.06%
Short % of Float	29.68%
Short Ratio (days to cover)	7.67

Income Statement

In the last 12 months, Prime Medicine had revenue of $3.85 million and -$202.01 million in losses. Loss per share was -$1.61.

Revenue	3.85M
Gross Profit	-151.57M
Operating Income	-206.52M
Pretax Income	-217.55M
Net Income	-202.01M
EBITDA	-200.01M
EBIT	-206.52M
Loss Per Share	-$1.61

Full Income Statement

Balance Sheet

The company has $144.26 million in cash and $121.15 million in debt, giving a net cash position of $23.11 million or $0.18 per share.

Cash & Cash Equivalents	144.26M
Total Debt	121.15M
Net Cash	23.11M
Net Cash Per Share	$0.18
Equity (Book Value)	106.92M
Book Value Per Share	0.84
Working Capital	129.48M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$104.02 million and capital expenditures -$7.39 million, giving a free cash flow of -$111.41 million.

Operating Cash Flow	-104.02M
Capital Expenditures	-7.39M
Free Cash Flow	-111.41M
FCF Per Share	-$0.87

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	-5,369.68%
Pretax Margin	-5,255.98%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Prime Medicine does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-32.05%
Shareholder Yield	-32.05%
Earnings Yield	-108.25%
FCF Yield	-59.70%

Analyst Forecast

The average price target for Prime Medicine is $9.38, which is 542.47% higher than the current price. The consensus rating is "Buy".

Price Target	$9.38
Price Target Difference	542.47%
Analyst Consensus	Buy
Analyst Count	6
Revenue Growth Forecast (5Y)	108.34%
EPS Growth Forecast (5Y)	-24.58%

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Prime Medicine has an Altman Z-Score of -3.38 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-3.38
Piotroski F-Score	3